Abstract: The present disclosure provides a compound having a first ligand LA of Formula I, In Formula I, each of Z1, Z2, and X1 to X4 is C or N; moiety A is a monocyclic ring or a polycyclic fused ring system; moiety C is a monocyclic ring or a polycyclic fused ring system; K is selected from the group consisting of a direct bond, O, S, N(R?), P(R?), B(R?), C(R?)(R?), and Si(R?)(R?); Y is a linking group; each R, R?, R?, R?, R1, R2, and R3 is hydrogen or a General Substituent defined herein; wherein one of the statements as defined herein is true. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of Formula Ir(LA)x(LB)y(LC)z is provided where x and y are independently 1 or 2; z is 0 or 1; and x+y+z=3; first ligand LA includes a structure of Formula I, ligand LB includes a structure of Formula II: and ligand LC is a bidentate ligand. In the compounds, moiety B is a polycyclic fused ring system comprising at least four rings; each of moiety C and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 to Z6 is C or N; L0 is a direct bond or a linking group; YA is a linking group; each substituent is hydrogen or a General Substituent defined herein; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: The present disclosure provides compound having a first ligand LA, including those comprising a structure of Formula A, In the compound, each of X1P to X6P is C, N, or B, where at least one of X1P to X6P is N or B; at least four substituent pairs selected from (R1, R2), (R2, R3), (R3, R4), (R4, R5), (R5, R6), and (R6, R1) are joined or fused together to form rings fused to the center ring P; each of R1, R2, R3, R4, R5, and R6 is independently a hydrogen or a General Substituents defined herein; LA is coordinated to a metal M to form a 5-membered or 6-membered chelate ring; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing such compounds are also provided.

Abstract: A compound having a first ligand LA including a structure of Formula I, is provided. In Formula I, each of moiety B and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X5 is C or N; ring C is bonded to ring A by a C; K is a direct bond or a linking group; each RA, RB, RC, and RD is hydrogen or a General Substituent defined herein; at least one RC or RD comprises an electron-withdrawing group; and LA is coordinated to a metal M through the dashed lines. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A homoleptic or heteroleptic compound of Formula Ir(LA)x(LB)y(LC)z is provided where LA comprises a structure of Formula I, LB comprises a structure of Formula II, and LC comprises a structure of Formula III, In Formula I, Formula II, and Formula III, each of Z1 to Z12 is C or N; each of moiety A, and moiety C to moiety F is a monocyclic ring or a polycyclic fused ring system; at least one of RA to RF comprises a cyano-substituted alkyl; each RA to RF is hydrogen or a General Substituent defined herein; and at least one of the following is true: (1) moiety B is comprised of four or more fused rings; (2) moiety B is comprised of three fused rings, and at least one RA or RB is a cyclic group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound including a first ligand LA of is provided. In Formula I, each of moiety A and moiety B is a monocyclic ring or a polycyclic fused ring system; each of Z1 to Z4 is C or N; each of K1 and K2 is a direct bond or a linker; L is a direct bond or a linker; at least one RA or RB includes the structure, where G is C, Si, or Ge; each substituents is hydrogen or a General Substituent; and LA is coordinated to a metal M by the dashed lines. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, each of moiety A, moiety B, and moiety C is ring or a polycyclic fused ring system; each of X and Z1 to Z5 is C or N; Y is N, B, and P; each of K1 and K2 is a direct bond or a linker; each R?, R?, RA, RB, and RC is hydrogen or a General Substituent defined herein; any two substituents can be joined or fused together to form a ring; and the ligand LA is coordinated to a metal M by the dashed lines. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I?, or Formula I*: In Formula I? or Formula I*, all the variables are defined herein; and LA is coordinated to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Provided are organometallic compounds comprising two moieties A and B which are each independently a monocyclic ring or a polycyclic fused ring structure, wherein the monocyclic ring or each ring of the polycyclic fused ring structure is independently a 5-membered to 10-membered carbocyclic or heterocyclic ring which are linked by a direct bond and which are further bridged by a linker comprising two groups which are each independently selected from the group consisting of O, S, Se, NR, BR, BRR?, PR, CR, C?O, C?NR, C?CRR?, C?S, CRR?, SO, SO2, P(O)R, SiRR?, and GeRR?. Also provided are formulations comprising these organometallic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.

Abstract: A compound having a formula of M(LA)x(LB)y(LC)z is provided. In the formula, each of LA, LB, and LC is a bidentate ligand; M is a metal; LA has a structure of Formula I, moiety A is a monocyclic ring or a polycyclic fused ring system; moiety B is a polycyclic ring system comprising two 6-membered rings; Z1 to Z4 are C or N; K1 and L1 are each a direct bond or a linker; each R?, R?, RA and RB is hydrogen or a General Substituent; at least one RA or RB comprises RW, where RW has a structure of Formula II, or Formula III, In formulas II and III, R1 and R2 are H, D, or F; R3 is H, D, or alkyl; and at least one of R1 or R2 is H or D. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of formula Ir(LA)x(LB)y(LC)z, where x and y are 1 or 2; z is 0 or 1; and x+y+z=3. In the compound, LA comprises Formula I, ligand LB comprises Formula II, and ligand LC is a bidentate ligand. In Formulas I and II, moiety A is a monocyclic ring or a polycyclic fused ring system; each of X1 to X14 is C or N; Y is a linking group; each R1-R2, R, R?, and RA-RE is hydrogen or a General Substituent defined herein; at least one of R1 and R2 is a tertiary alkyl group; and (1) at least one pair of RB or RC substituents are joined or fused to form a ring, or (2) at least one RC or RB comprises an electron-withdrawing group other than nitrile, or (3) X11 is N, R1 is a tertiary alkyl group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, moiety A is a 5-membered or 6-membered ring; moiety B is a fused ring structure comprising at least four rings; K is a direct bond, O, or S; each of Z1 and Z2 is independently C or N; each RA and RB is independently hydrogen or a General Substituent; at least one RB comprises a cyclic group or an electron-withdrawing group; LA is coordinated to a metal M that has an atomic mass of at least 40 and is optionally coordinated to other ligands; and the ligand LA is optionally linked with other ligands. Formulations, OLEDs, and consumer products including the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, each of X1 to X6 is C or N; K is a direct bond or a linker; each of L1 and L2 is a linker; each R, R?, R?, R?, RA, and RB is hydrogen or a General Substituent defined herein; two RB are joined to form a ring; LA is coordinated to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of Ir(LA)m(LB)3-m, having a structure of is provided. In Formula I or Formula II, moieties A and B are each either a monocyclic ring or a polycyclic fused ring system; X1 to X8 and Z1 to Z4 are C or N; Y is a single atom linker, which can be substituted; each R1, R2, R3, R4, and R5 is hydrogen or a General Substituent; m is 1 or 2; at least one of R1, R2, and R3 comprises at least one first electron-withdrawing group; and at least one of R4 and R5 comprises at least one second electron-withdrawing group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided, where: each of moiety A and moiety B is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 and Z2 is C or N; K1 and K2 are each a direct bond or a linker; L1 is a direct bond or an organic linker; each R?, R?, RA and RB is hydrogen or a General Substituent defined herein; and at least one RA or one RB comprises R*, where R* is an alkyl group, a silyl group, a germyl group, or a combination thereof. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: This disclosure provides a compound, Ir(LA)p(LB)q(LC)r, where LA has a structure of Formula IA: LB has a structure of Formula IB: and LC is a bidentate ligand. In Formulas IA and IB, p and q are 1 or 2; r is 0 or 1; and p+q+r=3; moiety A is a monocyclic ring or a polycyclic fused ring system; Y is a linker that forms a 5-membered ring; each of Z1, Z2, and X1 to X16 is C or N; each substituent is hydrogen or a General Substituent defined herein; and at least one of RD or RE is a heterocycle, provided that (a) if RE is a heterocycle comprising one heteroatom, then p=1 and moiety A is not a fused imidazole; and (b) if one RD is pyridine, then each of X1-X8 is C. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Provided are organometallic compounds comprising a ligand LA which is at least bidentate and coordinated to a central metal atom selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Pd, Ag, Au, and Cu. Also provided are formulations comprising these organometallic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.

Abstract: Provided are organometallic compounds which comprise a ligand comprising a 6-membered aromatic carbocyclic or heterocyclic ring which is bond via a direct bond to a moiety which is a monocyclic 5-membered or 6-membered carbocyclic or heterocyclic ring or a polycyclic fused ring system comprising two or more 5-membered or 6-membered carbocyclic or heterocyclic rings. Also provided are formulations comprising these organometallic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.

Abstract: Provided is a compound having a formula of M(LA)(LB)(LC); where LA, LB and LC are each a bidentate ligand and are different from each other; M is selected from the group consisting of Ir, Os, Rh, Ru, Pt, and Pd; two or three of LA, LB and LC are optionally linked together to form a tetradentate or hexadentate ligand; LA has a structure of Formula I: where moieties A and B are each independently a monocyclic ring or a polycyclic fused ring system, where the monocyclic ring or each ring of the polycyclic fused ring system is independently a 5-membered to 10-membered carbocyclic or heterocyclic ring; X1 to X4 are each independently C or N; Z1 and Z2 are each independently C or N; K1 and K2 are each independently a direct bond, O, S, N(R?), P(R?), B(R?), C(R?)(R?), and Si(R?)(R?); Z1 is C if K1 is not a direct bond, Z2 is C if K2 is not a direct bond; L1 is a direct bond or an organic linker; RA and RB each independently represent mono to the maximum allowable substitution, or no substitution; wherein each R?

Abstract: Provided are organometallic compounds comprising a ligand which contains at least one group of three 5-membered or 6-membered carbocyclic or heterocyclic rings which are fused together so that they all share one central C or N atom. Also provided are formulations comprising these organometallic compounds. Further provided are organic light-emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.